CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies

Abstract

Original article can be found at: http://www.landesbioscience.com/journals/cbt/ Copyright Landes Bioscience [Full text of this article is not available in the UHRA]Background: Response assessment is critical in evaluating effectiveness of anticancer treatment. Tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC) are associated with significant clinical benefit but may not result in significant tumour size reduction. Thus standard size-based response assessment with RECIST is insensitive, resulting in low response rates which do not reflect disease control measured by time to progression. We compared the use of combined size and density response criteria with standard size based criteria in metastatic RCC patients treated with TKI's. Patients and methods: CT scans from 32 patients with metastatic RCC treated with either sunitinib (18) or cediranib (14) were assessed. 12 patients were excluded from the analysis as 10 had non-contrast enhanced scans due to renal impairment and 2 stopped treatment due to toxicity. Scans from 20 evaluable patients at baseline and 12 weeks on treatment were assessed using RECIST, Choi, and modified criteria in which both a 10% decrease in size and 15% decrease in density were required to define a partial response (PR). Response assessment performed using each of the three methods was compared with time to disease progression (TTP) defined by RECIST using Kaplan-Meier statistics and Log-rank test with significance at 5%. Results: Partial response (PR) and stable disease (SD) defined by modified criteria successfully identified patients with a long TTP (448 days) or short TTP (89 days) respectively (p=0.002). Neither RECIST nor standard Choi criteria successfully discriminated between patients having a short or long clinical benefit. Conclusion: A combined reduction in both size and arterial phase density of RCC metastases treated with TKIs correlates with TTP. RECIST and standard Choi criteria appear inferior

Quantification of Plasma Cell-Free DNA1in Predicting Therapeutic Efficacy of Sorafenib on Metastatic Clear Cell Renal Cell Carcinoma

“…However, cancers treated with sorafenib often show little change in size during early stage of therapy despite substantial clinical benefit. Radiologic criteria that additionally take into account functional changes in the enhancement of lesions on contrast materialenhanced CT scans or dynamic contrast-enhanced MRI have helped to identify patients who went on to show clinical benefit as early as 9 weeks into treatment [16][17][18]. Accordingly, studies on molecular markers in evaluation of metastatic RCC treatment are relevant.…”

How anti-angiogenic drugs are able to induce resistance to their own therapeutic effect in human metastatic renal carcinoma

“…In clinical settings, there is also radiological evidence of necrosis induced by anti-angiogenic drugs in patients with metastatic renal cell carcinoma. In addition, radiological criteria combining changes in tumor density and in tumor size [16][17] distinguish prognostic groups better than the standard criteria that only assess changes in tumor size [18] . As necrosis is an indirect marker of hypoxia, we decided to study the in vitro effect of experimental hypoxia on renal cancer stem cells sorted from these renal cell carcinoma xenografts.…”

Metastatic renal cell cancer

“…However, it has also been shown that a 10% reduction in the sum of largest diameters is a better predictor than the Choi criteria [10] . Using modified Choi criteria (a decrease in size 410% and a decrease in tumour attenuation 415%), Nathan et al [16] showed that such estimation is better correlated to time to progression than the Choi criteria. When contrast attenuation-based criteria are applied, standardization of the contrast phases is crucial.…”